-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Introduction: HBM7020 showed high-efficiency tumor killing in preclinical studies, while effectively inhibiting cytokine release.
-- Cambridge, Massachusetts, Rotterdam, Netherlands, and Suzhou, China, August 21, 2020 /AGENCY/ -- Global Innovative Biopharmaceuticals and Platinum Pharmaceuticals, in the clinical development phase, showcased their newly developed dual-specific antibody, BCMA x CD3 (HBM7020), at the Cell Engager Summit Forum.
HBM7020 and platinum medicine's own HBICETM (HCAb-based dual-specific cell bridger) platform research and development, with efficient tumor killing and can reduce the release of cytokines, can reduce the risk of clinical cytokine storm side effects, can be converted into more effective and safe therapy.
details have been displayed as posters at the Cell Engager Summit Forum on August 19, 2020 at 14:50 EST, and this year's Cell Engager Summit will be held online from August 18 to August 20, 2020.
B cell mature antigen (BCMA) is a highly differentiated plasma cell selective protein that is highly expressed in malignant plasma cells in patients with multiple myeloma (MM) and is an ideal target for T-cell targeted therapy.
, patients receiving BCMA targeted therapy are still subject to non-reactive, rapid recurrence, high toxicity caused by cytokine release syndrome, and short half-life.
BCMAxCD3, developed in combination with technology and platinum medicine, overcomes a number of limitations and promises to provide a new generation of therapies for patients with multiple myeloma.
HBM7020 is a new BCMA x CD3 dual-specific antibody developed independently using the HBICETM platform of Platinum Pharmaceuticals.
its "2 plus 1" structural design includes an anti-CD3 binding domain optimized to activate T-cell activity, and two anti-BCMA binding domains, thus having the effect of high efficiency and high selective killing of BCMA-positive MM cells, while controlling the release of cytokines.
HBM7020 effectively kills BCMA-positive tumor cells while reducing the risk of CRS (cytokine release syndrome) compared to its class BCMAx CD3 dual-specific antibodies.
HBM7020 represents a potentially better treatment for MM patients and other BCMA-positive tumors.
.
